EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort

Background: Beyond programmed death ligand 1 (PD-L1), no other biomarkers for immunotherapy are used in daily practice. We previously created EPSILoN (Eastern Cooperative Oncology Group performance status (ECOG PS), smoking, liver metastases, lactate dehydrogenase (LDH), neutrophil-to-lymphocyte rat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Prelaj, Arsela, Ferrara, Roberto, Rebuzzi, Sara Elena, Proto, Claudia, Signorelli, Diego, Galli, Giulia, De Toma, Alessandro, Randon, Giovanni, Pagani, Filippo, Viscardi, Giuseppe, Brambilla, Marta, Trevisan, Benedetta, Ganzinelli, Monica, Martinetti, Antonia, Gallucci, Rosaria, Di Mauro, Rosa Maria, Molino, Giuliano, Zilembo, Nicoletta, Torri, Valter, de Braud, Filippo Maria, Garassino, Marina Chiara, Lo Russo, Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6966664/
https://ncbi.nlm.nih.gov/pubmed/31817541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11121954
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados